Multisystem Inflammatory Syndrome in Children (MIS-C): Comparison of the First and the Second Waves

Mimi Ganguly1, Purbasha Gupta1, Debopama Biswas1

  • 1Pediatric Rheumatology Unit, Institute of Child Health, Kolkata, West Bengal.

Indian Pediatrics
|January 14, 2023
PubMed

Insights

The second wave of multisystem inflammatory syndrome in children (MIS-C) in India showed more Kawasaki disease-like symptoms, heart issues, and ICU admissions. Steroid treatment was also more common during the second wave.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Cardiology

Background:

  • Multisystem inflammatory syndrome in children (MIS-C) is a rare but serious condition.
  • The COVID-19 pandemic has seen distinct waves of infection, potentially impacting pediatric inflammatory syndromes.

Purpose of the Study:

  • To compare the clinical characteristics and outcomes of MIS-C patients during two distinct pandemic waves in Kolkata, India.
  • To identify differences in presentation, severity, and treatment between the two MIS-C waves.

Main Methods:

  • Retrospective analysis of MIS-C cases.
  • Comparison of patient demographics, clinical features, laboratory findings, and treatment modalities between July 2020-January 2021 and April-July 2021.

Main Results:

  • The second wave (April-July 2021) exhibited a higher incidence of Kawasaki disease (KD)-like presentations.
  • Cardiac involvement and pediatric intensive care unit (PICU) admissions were more frequent in the second wave.
  • Increased utilization of steroid therapy was observed during the second wave.

Conclusions:

  • The clinical profile and severity of MIS-C may evolve between pandemic waves.
  • Findings suggest a potential shift towards more severe, KD-like presentations with cardiac complications in the second wave.
  • This highlights the need for vigilant monitoring and tailored management strategies for MIS-C during different pandemic phases.